A completed KLK activome profile: Investigation of activation profiles of KLK9, 10, and 15

Biological Chemistry

Volumn 390, Issue 4, 2009, Pages 373-377

  Yoon, Hyesook ^a   Blaber, Sachiko I ^a   Debela, Mekdes ^b   Goettig, Peter ^b,c   Scarisbrick, Isobel A ^d   Blaber, Michael ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

^b MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^c UNIVERSITY OF SALZBURG   (Austria)

^d MAYO CLINIC   (United States)

Author keywords

Activation cascade; Activome; Kallikrein; Kallikrein related peptidases (KLKs); Protease

Indexed keywords

ARGININE; HYBRID PROTEIN; KALLIKREIN; KALLIKREIN 10; KALLIKREIN 15; KALLIKREIN 9; LYSINE; PREKALLIKREIN; PREKALLIKREIN 12; PREKALLIKREIN 14; PREKALLIKREIN 8; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN HYDROLYSIS;

ELECTROPHORESIS, AGAR GEL; GENE EXPRESSION PROFILING; HUMANS; KALLIKREINS; RECOMBINANT FUSION PROTEINS;

EID: 64849117485     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2009.026     Document Type: Article

References (41)

1. Blaber, S.I., Ciric, B., Christophi, G.P., Bernett, M., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. (2004). Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J. 18, 920-922.
2. Blaber, S.I., Yoon, H., Scarisbrick, I.A., Juliano, M.A., and Blaber, M. (2007). The autolytic regulation of human kallikrein-related peptidase 6. Biochemistry 46, 5209-5217.
3. Brattsand, M. and Egelrud, T. (1999). Purification, molecular cloning, and expression of a human stratum corneum trypsin-like serine protease with possible function in desquamation. J. Biol. Chem. 274, 30033-30040.
4. Brattsand, M., Stefansson, K., Lundh, C., Haasum, Y., and Egelrud, T. (2005). A proteolytic cascade of kallikreins in the stratum corneum. J. Invest. Dermatol. 124, 198-203.
5. Catalona, W.J., Besser, J.A., and Smith, D.S. (1997). Serum free prostate specific antigen and prostate specific antigen measurements for predicting cancer in men with prior negative prostatic biopsies. J. Urol. 158, 2162-2167.
6. Caubet, C., Jonca, N., Brattsand, M., Guerrin, M., Bernard, D., Schmidt, R., Egelrud, T., Simon, M., and Serre, G. (2004). Degradation of corneodesmosome proteins by two serine proteases of the kallikrein family, SCTE/KLK5/hK5 and SCCE/KLK7/hK7. J. Invest. Dermatol. 122, 1235-1244.
7. Clements, J.A. (1989). The glandular kallikrein family of enzymes: tissue-specific expression and hormonal regulation. Endocr. Rev. 10, 393-419.
8. Clements, J.A., Willemsen, N.M., Myers, S.A., and Dong, Y. (2004). The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit. Rev. Clin. Lab. Sci. 41, 265-312.
9. Darson, M.F., Pacelli, A., Roche, P., Rittenhouse, H.G., Wolfert, R.L., Saeid, M.S., Young, C.Y., Klee, G.G., Tindall, D.J., and Bostwick, D.G. (1999). Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 53, 939-944.
10. Debela, M., Magdolen, V., Schechter, N., Valachova, M., Lottspeich, F., Craik, C.S., Choe, Y., Bode, W., and Goettig, P. (2006). Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J. Biol. Chem. 281, 25678-25688.
11. Diamandis, E.P. and Yousef, G.M. (2001). Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Expert Rev. Mol. Diagn. 1, 182-190.
12. Diamandis, E.P., Yousef, G.M., Luo, L.Y., Magklara, A., and Obiezu, C.V. (2000). The new human kallikrein gene family: implications in carcinogenesis. Trends Endocrinol. Metab. 11, 54-60.
13. Emami, N. and Diamandis, E.P. (2008). Human kallikrein-related peptidase 14 (KLK14) is a new activator component of the KLK proteolytic cascade. J. Biol. Chem. 283, 3031-3041.
14. Evnin, L.B., Vasquez, J.R., and Craik, C.S. (1990). Substrate specificity of trypsin investigated by using a genetic selection. Proc. Natl. Acad. Sci. USA 87, 6659-6663.
15. Fuessel, S., Sickert, D., Meye, A., Klenk, U., Schmidt, U., Schmitz, M., Rost, A.K., Eweigle, B., Kiessling, A., and Wirth, M.P. (2003). Multiple tumor marker analyses (PSA, HK2, PSCA, tryp-p8) in primary prostate cancers using quantitative RT-PCR. Int. J. Oncol. 23, 221-228.
16. Kumar, A., Mikolajczyk, S.D., Goel, A.S., Millar, L.S., and Saedi, M.S. (1997). Expression of pro-form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res. 57, 3111-3114.
17. Liu, X.-L., Wazer, D.E., Watanabe, K., and Band, V. (1996). Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res. 56, 3371-3379.
18. Lovgren, J., Rajakoski, K., Karp, M., Lundwall, A., and Lilja, H. (1997). Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem. Biophys. Res. Commun. 238, 549-555.
19. Luderer, A., Chen, Y.-T., Soraino, T.F., Kramp, W.J., Carlson, G., Cuny, C., Sharp, T., Smith, W., Petteway, J., Brawer, K.M., and Thiel, R. (1995). Measurement of the proportion of free to total prostate specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of the total prostate specific antigen. Urology 46, 187-194.
20. Lundstrom, A. and Egelrud, T. (1991). Stratum corneum chymotryptic enzyme: a proteinase which may be generally present in the stratum corneum and with a possible involvement in desquamation. Acta Derm. Venereol. 71, 471-474.
21. Lundwall, A., Band, V., Blaber, M., Clements, J.A., Courty, Y., Diamandis, E.P., Fritz, H., Lilja, H., Malm, J., Maltais, L.J., Olsson, A.Y., et al. (2006). A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol. Chem. 387, 637-641.
22. 2+, a tight-binding inhibitor. Prostate 45, 132-139.
23. Michael, I.P., Sotiropoulou, G., Pampalakis, G., Magklara, A., Ghosh, M., Wasney, G.A., and Diamandis, E.P. (2005). Biochemical and enzymatic characterization of human kallikrein 5 (hK5), a novel serine protease potentially involved in cancer progression. J. Biol. Chem. 280, 14628-14635.
24. Michael, I.P., Pampalakis, G., Mikolajczyk, S.D., Malm, J., Sotiropoulou, G., and Diamandis, E.P. (2006). Human tissue kallikrein 5 (hK5) is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in prostate cancer progression. J. Biol. Chem. 281, 12743-12750.
25. Pampalakis, G. and Sotiropoulou, G. (2007). Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim. Biophys. Acta 1776, 22-31.
26. Ramsay, A.J., Dong, Y., Hunt, M.L., Linn, M., Samaratunga, H., Clements, J.A., and Hooper, J.D. (2008). Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are coexpressed during prostate cancer progression. J. Biol. Chem. 283, 12293-12304.
27. Recker, F., Kwiatkowski, M.K., Piironen, T., Pettersson, K., Huber, A., Lummen, G., and Tscholl, R. (2000). Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 55, 481-485.
28. Scarisbrick, I.A., Blaber, S.I., Tingling, J.T., Rodriguez, M., Blaber, M., and Christophi, G.P. (2006). Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J. Neuroimmunol. 178, 167-176.
29. Scarisbrick, I.A., Linbo, R., Vandell, A.G., Keegan, M., Blaber, S.I., Blaber, M., Sneve, D., Lucchinetti, C.F., Rodriguez, M., and Diamandis, E.P. (2008). Tissue kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol. Chem. 389, 739-745.
30. Schmidt, A.E., Ogawa, T., Gailani, D., and Bajaj, S.P. (2004). Structural role of Gly193 in serine proteases. J. Biol. Chem. 279, 29485-29492.
31. Singh, J., Naran, A., Misso, N.L., Rigby, P.J., Thompson, P.J., and Bhoola, K.D. (2008). Expression of kallikrein-related peptidases (KRP/hK5, 7, 6, 8) in subtypes of human lung carcinoma. Int. Immunopharmacol. 8, 300-306.
32. Sotiropoulou, G., Rogakos, V., Tsetsenis, T., Pampalakis, G., Zafiropoulos, N., Simillides, G., Yiotakis, A., and Diamandis, E.P. (2003). Emerging interest in the kallikrein gene family for understanding and diagnosing cancer. Oncol. Res. 13, 381-391.
33. Stamey, T.A., Yang, N., Hay, A.R., McNal, J.E., Freiha, F.S., and Redwine, E. (1987). Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 15, 909-916.
34. Takayama, T.K., Fujikawa, K., and Davie, E.W. (1997). Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J. Biol. Chem. 272, 21582-21588.
35. Vaisanen, V., Lovgren, J., Hellman, J., Piironen, T., Lilja, H., and Pettersson, K. (1999). Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis. 2, 91-97.
36. Yoon, H., Laxmikanthan, G., Lee, J., Blaber, S.I., Rodriguez, A., Kogot, J.M., Scarisbrick, I.A., and Blaber, M. (2007). Activation profiles and regulatory cascades of the human kallikrein-related proteases. J. Biol. Chem. 282, 31852-31864.
37. Yoon, H., Blaber, S.I., Evans, D.M., Trim, J., Juliano, M.A., Scarisbrick, I.A., and Blaber, M. (2008). Activation profiles of human kallikrein-related peptidases by proteases of the thrombostasis axis. Protein Sci. 17, 1998-2007.
38. Yousef, G. and Diamandis, E.P. (2000). The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics 65, 184-194.
39. Yousef, G.M. and Diamandis, E.P. (2001). The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev. 22, 184-204.
40. Yousef, G.M., Scorilas, A., Jung, K., Ashworth, L.K., and Diamandis, E.P. (2001). Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J. Biol. Chem. 276, 53-61.
41. Yousef, G.M., Kapadia, C., Polymeris, M.E., Borgono, C., Hutch-inson, S., Wasney, G.A., Soosaipillai, A., and Diamandis, E.P. (2003). The human kallikrein protein 5 (hK5) is enzymatically active, glycosylated and forms complexes with two protease inhibitors in ovarian cancer fluids. Biochim. Biophys. Acta 1628, 88-96.